Sometime ago, Scuderia Ferrari were in a bit of hot water over sponsorship issues. The main problem was their title sponsor, Mission Winnow, who are owned by tobacco giants, Phillip Morris. Since Australia has strict anti-tobacco laws, Ferrari was in a bit of a fix.
Luckily, they have been able to get around the issue and race in Melbourne without the likelihood of causing controversy. The Maranello outfit unveiled a revised livery for the season-opening weekend in Melbourne.
The Italian squad were compelled to remove all traces of its ‘Mission Winnow’ title sponsor branding for the race. The decision came on the back of an investigation on whether it breaches anti-tobacco advertising laws.
ADVERTISEMENT
Article continues below this ad
Since the branding covers a significant portion of the SF90, Ferrari found a way around it. So, instead of a blank space where the brand used to be, a massive ’90 Years’ decal has been added. This is significant as Scuderia Ferrari are celebrating their 90th anniversary since the founding of the racing team in 1929.
Celebrating our 90th anniversary in Melbourne https://t.co/dIBYboDeZ4#AusGP #essereFerrari #ScuderiaFerrari90 pic.twitter.com/GFMDdvaPpn
— Scuderia Ferrari (@ScuderiaFerrari) March 12, 2019
The anniversary logos will adorn the car, driver overalls and team equipment. There was also talk of the team using their 2018 overalls for the race.
ADVERTISEMENT
Article continues below this ad
In Formula 1 alone, it has taken 16 Constructors’ titles and 15 Drivers’. In the world of endurance racing, Ferrari has nine victories to its name in the Le Mans 24 Hours, two at Daytona and five FIA WEC titles and has even been successful in rallying.
For now, all the teams, including Ferrari will be focusing on the race this weekend as the pecking order will be decided. The team will be fielding Monegasque driver, Charles LeClerc alongside Sebastian Vettel this season. In addition to that, Mattia Binotto is the new team principal, taking over the reins of the Prancing Horse from Maurizio Arrivabene.
ADVERTISEMENT
Article continues below this ad